Likes Received
Top 10 Influencers in 2024$XTALPI(02228.HK) $Tesla(TSLA.US) We must see that the current capabilities of LLM are very strong, but it is still spinning in the digital world. The reason why we have not yet felt the huge impact of AI on daily life is fundamentally because the application of AI has not been truly effectively implemented, that is, AI has not truly transformed our lives. From my personal investment perspective, I believe the two biggest opportunities for AI applications currently are: innovative medicine (significantly improving the efficiency of trial and error through AI), and FSD (completely transforming human transportation and logistics efficiency). It is precisely because of this belief that I have invested in Jingtai Technology and RXRX. We are on the eve of transformation! So, tell yourself, stay calm and keep your positions stable.
$XTALPI(02228.HK) The renowned biopharmaceutical media Endpoints has also recognized the transformative impact of AI on the pharmaceutical industry, to the extent that traditional medical commentators can no longer ignore it. As a result, they surveyed 400 readers in the pharmaceutical field and compiled a report. The final conclusion is: AI's current influence is fragmented and fraught with issues—but expectations for the next five years are as absurdly high as a triple-shot morning in Silicon Valley. Pharmaceutical executives and scientists are the most optimistic about AI's prospects, with over 78% of respondents believing AI will revolutionize drug R&D within 3-5 years. The financial sector, however, remains skeptical, with only 53% believing AI will have a significant impact on the pharmaceutical industry by 2030.@Zhou Shuren's Trader@Boss's Boss Dolphin Spokesperson This reveals part of the reason for the volatility of companies like Jingtai in the capital market.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
